Select Page

Southwest Prostate Cancer Symposium

Scottsdale, Arizona

October 17-19, 2024

innovations in urologic practice logo

A Must-Attend Event!

The Southwest Prostate Cancer Symposium (SPCS 2024) is intended for urologists, radiation oncologists, medical oncologists, and other healthcare professionals involved in the treatment of prostate cancer. It will educate the attendees about advances in the management of localized and advanced prostate cancer, with a focus on imaging, technology, and training in the related devices.

The goal of this educational program is to equip urologists, radiation oncologists, medical oncologists, and other healthcare professionals involved in prostate cancer care with the up-to-date clinical knowledge and tools they need to best treat their patients. The program aims to provide a technical update on all aspects of diagnosis and treatment of localized and advanced disease.

Program Co-Chair

Nelson N. Stone, MD

Nelson N. Stone, MD

Professor of Urology and
Radiation Oncology
Icahn School of Medicine at Mount Sinai
New York, New York

Program Co-Chair

Richard G. Stock, MD

Richard G. Stock, MD

Professor of Radiation Oncology
Director of Genito-Urinary
Radiation Oncology
Icahn School of Medicine at Mount Sinai
New York, New York

Program Co-Chair

William K. Oh, MD

William K. Oh, MD

Clinical Professor of Medicine
Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, New York

Agenda

Join us from October 17-19, 2024 in Scottsdale, Arizona.

This is a working agenda and subject to change. Please check back often for the latest updates.

Note: All industry activities will be held in a separate room.

TimeCourse TitleSpeaker(s)
Thursday, October 17, 2024 (ALL TIMES MOUNTAIN STANDARD TIME)
6:30am–7:00pmRegistration and Check-In
7:00am–7:50amIndustry-Supported Breakfast Program
8:00am–5:30pmExhibits Open
8:00am–8:10amWelcome and IntroductionProgram Co-Chair: Nelson N. Stone, MD
8:10am–10:30amSession 1: Application of Artificial Intelligence (AI) for Prostate Cancer Diagnosis and ManagementModerator: Nelson N. Stone, MD
8:10am–8:30amHow AI Improves Imaging InterpretationAlberto Vargas, MD
8:30am–8:50amRole of Digital Pathology and AI in Improving Diagnostic AccuracyDavid G. Bostwick, MD, MBA, FCAP
8:50am–9:10amAdaptive RadiotherapySeth R. Blacksburg, MD
9:10am–9:30amAI and Machine Learning: What the Future HoldsSigrid V. Carlsson, MD, PhD, MPH
9:30am–9:50amUse of AI to Develop Training Platforms: Is Big Brother Watching?Nelson N. Stone, MD
9:50am-10:30amPanel Discussion
10:30am-10:45amBreak and Visit Exhibits
10:45am–12:10pmSession 2: Targeted and Molecular ImagingModerator: E. David Crawford, MD
10:45am-11:05amRadiolabeled Metabolic AnaloguesRichard G. Stock, MD
11:05am-11:25amTargeted Prostate-Specific Membrane Proteins and ReceptorsAlberto Vargas, MD
11:25am–11:45amRADAR and Image SequencingE. David Crawford, MD
11:45am-12:10pmPanel Discussion
12:10pm–1:00pmIndustry-Supported Lunch Symposium
1:00pm–1:15pmBreak and Visit Exhibits
1:15pm–3:20pmSession 3: Genetic Implications for Prostate CancerModerator: Alan H. Bryce, MD
1:10pm—1:30pmShould Screening be Altered Based on Germline and Family History?Sigrid V. Carlsson, MD, PhD, MPH
1:30pm–1:50pmImplications of Genomic Heterogeneity on Biopsy SpecimensDavid G. Bostwick, MD, MBA, FCAP
1:50pm-2:10pmUse of Novel Markers to Inform Adjuvant TherapyE. David Crawford, MD
2:10pm-2:40pmUsing Genetic Testing in Prostate Cancer: When and HowAlan H. Bryce, MD
2:40pm-3:20pmPanel Discussion
3:20pm–3:35pmBreak and Visit Exhibits
3:35pm–5:30pmSession 4: ImmunotherapyModerator: William K. Oh, MD
3:35pm-3:55pmIntra-tumoral Immunotherapy for Cancer: Update 2024 of a Novel ApproachDavid G. Bostwick, MD, MBA, FCAP
3:55pm-4:25pmSystemic Immunotherapy in Prostate CancerWilliam K. Oh, MD
4:25pm-4:45pmDiet, Exercise, and Lifestyle: What Do We Know?Sigrid V. Carlsson, MD, PhD, MPH
4:45pm-5:30pmPanel Discussion
6:00pm-7:30pmWelcome Reception
Friday October 18, 2024 (ALL TIMES MOUNTAIN STANDARD TIME)
6:30am–5:00pmRegistration and Check-In
7:00am–7:45amIndustry-Supported Breakfast Symposium
8:00am–6:00pmExhibits Open
8:00am–9:50amSession 5: Intermediate and Locally Advanced DiseaseModerator: Richard G. Stock, MD
8:00am–8:20amRadiobiology: IGRT vs. SBRT vs. BrachytherapyRichard G. Stock, MD
8:20am–8:40amRadiation Dose and Hormone Therapy: How much is Enough?Nelson N. Stone, MD
8:40am–10:10amIs there a Preferred Treatment for Intermediate Risk Prostate Cancer? Debate
8:40am–9:00amSBRTRichard G. Stock, MD
9:00am–9:20amBrachytherapyJohn Sylvester, MD, FABS
9:20am–9:40amFocal TherapyNelson N. Stone, MD
9:40am–10:10amPanel Discussion
10:10am–10:25amBreak and Visit Exhibits
10:25am–10:50amKeynote Lecture: Has Prostate Cancer Mortality Increased?Sigrid V. Carlsson, MD, PhD, MPH
10:50am–12:40pmSession 6: Novel Approaches to the Treatment of Metastatic Prostate CancerModerator: Alberto Vargas, MD
10:50am–11:10amBiology of the Radiotheranostic ApproachAlberto Vargas, MD
11:10am–11:30ammCRPC: Lu-177 PSMA and BeyondWilliam K. Oh, MD
11:30am–11:50amOligometastatic Disease: When and Where RadiotherapyRichard G. Stock, MD
11:50am–12:10pmShould We Treat the Primary in Newly Diagnosed Metastatic Prostate Cancer?John E. Sylvester, MD
12:10pm–12:40pmPanel Discussion
12:40pm–1:30pmIndustry-Supported Lunch Symposium
1:30pm–1:50pmBreak and Visit Exhibits
1:50pm–4:15pmSession 7: Advances in Metastatic DiseaseModerator: Mary-Ellen Taplin, MD
1:50pm–2:10pmTreatment of Oligometastatic DiseaseMary-Ellen Taplin, MD
2:10pm–2:30pmHormone-sensitive Metastatic Disease: 1, 2 or 3 Drugs?Alan H. Bryce, MD
2:30pm–2:50pmOptimal Management of Biochemical RecurrenceMary-Ellen Taplin, MD
2:50pm–3:10pmCardiovascular Side Effects of New Hormone TherapiesWilliam K. Oh, MD
3:10pm–3:30pmNovel Targeted Treatments for Metastatic DiseaseAlan H. Bryce, MD
3:30pm–3:40pmBreak & Visit Exhibits
3:40pm–4:00pmTreating Neuroendocrine Prostate CancerWilliam K.Oh, MD
4:00pm-4:15pmPanel Discussion
4:15pm-6:00pmSession 8: Epidemiology and Early DetectionModerator: Sigrid V. Carlsson, MD, PhD, MPH
4:15pm-4:35pmScreening Guidelines for Prostate Cancer: Do We Have Consensus?Sigrid V. Carlsson, MD, PhD, MPH
4:35pm-4:55pmUpdate on New Biomarkers for Prostate CancerE. David Crawford, MD
4:55pm-5:15pmProstate MRI as a Screening and Surveillance ToolAlberto Vargas, MD
5:15pm-5:35pmPSMA-targeted PET in the Diagnosis and Staging of Prostate CancerMichael A. Gorin, MD
5:35pm-6:15pmPanel Discussion
Saturday, October 19, 2024 (ALL TIMES MOUNTAIN STANDARD TIME)
6:30am–7:00amRegistration and Check-In
7:00am–7:50amIndustry-Supported Breakfast Program
8:00am–12:00pmExhibits Open
8:00am–9:30amSession 9: New Transperineal Procedures: Technical ConsiderationsModerator: Michael A. Gorin, MD
8:00am–8:20amTransperineal Prostate Biopsy in the Office Setting: Anesthetic ConsiderationsMichael A. Gorin, MD
8:20am-8:40amHow Biopsy Core Length Affects Diagnostic AccuracyDavid G. Bostwick, MD, MBA, FCAP
8:40am-8:55amHydrogel Rectal Spacer: Radiopaque vs. Non-radiopaqueRichard G. Stock, MD
8:55am–9:10amHyaluronic Acid Rectal Spacer: Are There Technical Advantages?John E. Sylvester, MD, FABS
9:10am–9:30amBiodegradable Rectal Balloon SpacingShawn H. Zimberg, MD
9:30am-12:30pmSession 10: Rotating Hands-on Workshops Using Prostate PhantomsModerator Nelson. N. Stone, MD
Attendees will rotate through the 3 workshops and the case presentations in the ballroom every 30 minutes.
9:30am-11:00amTransperineal Biopsy
Station 1: Fusion BiopsyMichael A. Gorin, MD
Station 2: Transperineal/Transrectal Biopsy Utilizing Variable Length NeedleE. David Crawford, MD, and David G. Bostwick, MD, MBA, FCAP
Ballroom: Radiation Therapy Case ReportsRichard G. Stock, MD; John E. Sylvester, MD, FABS; Seth R. Blacksburg, MD; Shawn H. Zimberg, MD
11:00am-12:30pmRectal Spacing
Station 1: Hydrogel SpacingRichard G. Stock, MD
Station 2: Hyaluronic Acid SpacingJohn E. Sylvester, MD, FABS
Station 3: Rectal Balloon SpacingShawn H. Zimberg, MD
Ballroom: Advanced Disease Case PresentationsWilliam K. Oh, MD, Mary-Ellen Taplin, MD, and Alan H. Bryce, MD
12:30pmAdjourn
​

Help us promote SPCS 2024!

We’ve built a social media toolkit to help you spread the word about the meeting to your friends and colleagues. We hope you’ll help us generate awareness because we all benefit from getting together and learning. Thanks!

Accommodations

The Westin Kierland Resort room block for the conference is sold out.

Westin Kierland Resort
6902 East Greenway Parkway
Scottsdale, AZ 85254
1-480-624-1000

Discover a vitalizing oasis at The Westin Kierland Resort & Spa in Scottsdale, Arizona. Located near versatile dining and shopping at Kierland Commons, our hotel offers a stimulating experience in the Sonoran Desert. Thrill your kids at OdySea Aquarium, featuring SeaTrek Helmet Diving and a shark tour. Challenge yourself at The Westin Kierland Golf Club, our award-winning course designed by Scottsdale architect Scott Miller. Agave, The Arizona Spa & Salon, offers rejuvenating facials, manicures, pedicures, makeup services, and scalp treatments. End your day with a personalized in-room massage or simply recharge on your soft Heavenly® Bed. Experience something new and refreshing at our resort.

CONFERENCE ATTIRE:
Attire is business casual. Since meeting room temperatures and personal comfort levels vary, it is recommended that you bring a sweater or jacket to the educational activities.

Transportation

GROUND TRANSPORTATION:
We suggest Uber and Lyft. 

Here are some shuttle options we found but do not have experience with:

For information about activities in Scottsdale, see this page from the Westin Kierland Resort: https://www.marriott.com/hotels/local-things-to-do/phxws-the-westin-kierland-resort-and-spa/

Invited Faculty

Seth R. Blacksburg, MD, MBA

Seth R. Blacksburg, MD, MBA

Accuray
New York, New York

David G. Bostwick, MD, MBA, FCAP

David G. Bostwick, MD, MBA, FCAP

Triopsy Medical, Inc.
Aurora, Colorado

Alan H. Bryce, MD

Alan H. Bryce, MD

City of Hope Cancer Center
Phoenix, Arizona

Sigrid V. Carlssson, MD, PhD, MPH

Sigrid V. Carlssson, MD, PhD, MPH

Memorial Sloan-Kettering Cancer Center
New York, New York

E. David Crawford, MD

E. David Crawford, MD

University of California, San Diego
La Jolla, California

Michael A. Gorin, MD

Michael A. Gorin, MD

Mount Sinai Medical Center
New York, New York

John E. Sylvester, MD, FABS

John E. Sylvester, MD, FABS

GenesisCare
Lakewood Ranch, Florida

Mary-Ellen Taplin, MD

Mary-Ellen Taplin, MD

Dana-Farber Cancer Institute
Boston, Massachusetts

Alberto Vargas, MD

Alberto Vargas, MD

New York University Grossman School of Medicine
New York, New York

Shawn H. Zimberg, MD

Shawn H. Zimberg, MD

Solaris Health
New Hyde Park, New York

CME Information

This activity is jointly provided by Medical Education Resources and Carden Jennings Publishing Co., Ltd.

This activity is supported by an educational grant from:

Educational Objectives

  1. Describe the applications of artificial intelligence in prostate cancer management and diagnosis, including machine learning, developing training platforms, digital pathology, and adaptive radiotherapy
  2. Describe the new field of targeted and molecular imaging to help physicians better stage patients with metastatic prostate cancer
  3. Assess the implications of genetic testing and germline and family history in staging patients with advanced disease
  4. Discuss updated information in immunotherapy for prostate cancer, especially intra-tumoral immunotherapy
  5. Analyze the evolving guidelines for early detection of prostate cancer and the role of new biomarkers and MRI as screening and surveillance tools
  6. Examine state-of-the-art imaging and therapies for metastatic prostate cancer
  7. Determine the advantages and disadvantages of the treatment options for intermediate and locally-advanced prostate cancer, including hormone therapy, radiations, SBRT, and IGRT
  8. Distinguish the advantages and risks of new transperineal biopsy procedures and radioprotection procedures
  9. Explain fusion biopsy, how to take a variable length prostate biopsy, and how to insert different rectal spacing devices on prostate phantoms to prepare for performing these procedures on patients 

Disclosure of Relevant Financial Relationships

Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies relevant financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported relevant financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality CE activities that promote improvements or quality in health care and not the business interest of an ineligible company.

In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Carden Jennings Publishing. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit: Medical Education Resources designates this live activity for a maximum of 18 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit: Medical Education Resources designates this live activity for a maximum of 18 ANCC nursing contact hours. Nurses will be awarded contact hours upon successful completion of the activity.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 18 contact hours.

Physician Assistant Credit: Medical Education Resources has been authorized by the American Academy of Physician Assistants (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 18 AAPA Category 1 CME Credits. Physician Assistants should only claim credit commensurate with the extent of their participation.

Pharmacy Credit: Medical Education Resources (MER) designates this continuing education activity for 18 contact hours (1.8 CEUs) of the Accreditation Council for Pharmacy Education. 
(Universal Program Number – JA 0003680-9999-24-172-L01-P

This activity is certified as Knowledge based CPE.

Registration

By registering for this conference, you agree to our standard Conference Registration and Attendance Terms and Conditions agreement, which is available online at: Conference Registration and Attendance Terms and Conditions.

Support Opportunities

To inquire about support opportunities, please contact:

Denise Castetter, Senior Director of Corporate Relations
Cell: 973-769-1020
Fax: 434-817-2020  • dcastetter@cjp.com

Meeting organized by Grand Rounds in Urology, a division of Carden Jennings Publishing, Co., Ltd.

Jointly provided by Medical Education Resources and
Carden Jennings Publishing Co., Ltd.

View content from previous Southwest Prostate Cancer Symposium meetings